Medicus Pharma to Host Third Quarter 2026 Financial Performance and Business Update Call on November 9, 2026

PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that it will host a financial performance and business update conference call on Monday, November 9, 2026, at 11:30 a.m. Eastern Time, following the filing of its Quarterly Report on Form 10-Q for the period ended September 30, 2026.

During the call, amongst other things, management will discuss the strategy relating to the Company’s decision to enter the CD228V Co-development and licensing agreement with Pfizer, Inc. (“Pfizer”) and proposed SkinJect® business combination (“Business Combination”) with an undisclosed special purpose acquisition company (“SPAC”) and concurrent financing non-binding Letter of Intent (“LOI”).